Amedisys Q2 Adj EPS $1.37 Beats $1.09 Estimate, Sales $553.00M Miss $568.20M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amedisys (NASDAQ:AMED) reported Q2 adjusted earnings of $1.37 per share, beating the analyst consensus estimate of $1.09 by 25.69%. However, the company's quarterly sales of $553.00 million missed the analyst consensus estimate of $568.20 million by 2.68%. This represents a 6.8% decrease in earnings and a 0.88% decrease in sales compared to the same period last year.
July 26, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amedisys reported better than expected Q2 earnings but lower than expected sales. This mixed result could lead to uncertainty in the market.
Amedisys reported Q2 earnings that beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is negative. The mixed results could lead to uncertainty in the market, potentially impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100